Three times as many deaths in the study arm vs. the control arm in a trial of ADC's Zynlonta have ra...
ADC Therapeutics' shares plummet after patient deaths in trial of Zynlonta
Three times as many deaths in the study arm vs. the control arm in a trial of ADC's Zynlonta have raised questions about the antibody-drug conjugate.
Author: Fierce Pharma
Read Original Article